Other disclosuresNSE SME · ACCPL
Accretion Pharmaceuticals Limited
Press Release
01 / The disclosure
What the company shared
Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2026, titled "Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%".
Exchange-provided summary Company profile
A question for your research
Read the underlying filing for the complete disclosure and any conditions not included in the exchange summary.
The evidence
Read the source excerpts
PDF text is unavailable. Read the original filing for the full disclosure.
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 106838316
- First collected
- 31 Oct 2026, 17:25 IST
- PDF extraction
- metadata_only
You’ve reached the end of this disclosure.